Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

Breast Cancer Research and Treatment

Volumn 121, Issue 3, 2010, Pages 539-553

  Tu, Shih Hsin ^a,b   Chang, Chih Chiang ^c   Chen, Ching Shyang ^b,d   Tam, Ka Wai ^b,c   Wang, Ying Jan ^e   Lee, Chia Hwa ^c   Lin, Hsiao Wei ^c   Cheng, Tzu Chun ^c   Huang, Ching Shui ^a,b   Chu, Jan Show ^b   Shih, Neng Yao ^f   Chen, Li Ching ^c   Leu, Sy Jye ^b   Ho, Yuan Soon ^c   Wu, Chih Hsiung ^b  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Breast cancer; Enolase 1; Estrogen receptor alpha; Nuclear factor kappa B; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ALPHA ENOLASE; ESTROGEN RECEPTOR; MESSENGER RNA; SMALL INTERFERING RNA; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER RESISTANCE; CANCER SIZE; CANCER TISSUE; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE FREE INTERVAL; DOWN REGULATION; DRUG CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELLS, CULTURED; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; NF-KAPPA B; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77953122846     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0492-0     Document Type: Article

References (50)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30
2. Dodwell D, Williamson D (2008) Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. Cancer Treat Rev 34:137-144 (Pubitemid 351372884)
3. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513-529
4. Chen B, Wang Y, Kane SE, Chen S (2008) Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells. J Mol Endocrinol 41:367-377
5. Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG, Kang KW (2008) Increased expression of Nrf2/AREdependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 45:537-546
6. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S (2008) Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 68:4910-4918
7. Honorat M, Mesnier A, Vendrell J, Guitton J, Bieche I, Lidereau R, Kruh GD, Dumontet C, Cohen P, Payen L (2008) ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 15:125-138
8. Lebioda L, Stec B (1988) Crystal structure of enolase indicates that enolase and pyruvate kinase evolved from a common ancestor. Nature 333:683-686
9. Chi-Shing Cho W (2007) Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 61:515-519 (Pubitemid 47570078)
10. Horiatis D, Wang Q, Pinski J (2004) A new screening system for proliferation-independent anti-cancer agents. Cancer Lett 210: 119-124 (Pubitemid 38692596)
11. Riby JE, Firestone GL, Bjeldanes LF (2008) 3, 3′-diindolylmethane reduces levels of HIF-lalpha and HIF-1 activity in hypoxic cultured human cancer cells. Biochem Pharmacol 75:1858-1867
12. Sims PA, Menefee AL, Larsen TM, Mansoorabadi SO, Reed GH (2006) Structure and catalytic properties of an engineered heterodimer of enolase composed of one active and one inactive subunit. J Mol Biol 355:422-431
13. Chang YS, Wu W, Walsh G, Hong WK, Mao L (2003) Enolasealpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 9:3641-3644 (Pubitemid 37169229)
14. Ray R, Miller DM (1991) Cloning and characterization of a human c-myc promoter-binding protein. Mol Cell Biol 11:2154-2161 (Pubitemid 21895587)
15. Subramanian A, Miller DM (2000) Structural analysis of alphaenolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem 275:5958-5965 (Pubitemid 30115245)
16. Fan P, Wang J, Santen RJ, Yue W (2007) Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 67:1352-1360 (Pubitemid 46270796)
17. Aerts JL, Gonzales MI, Topalian SL (2004) Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. Biotechniques 36:84-86, 88, 90-91
18. Chen F, Kim E, Wang CC, Harrison LE (2005) Ciglitazoneinduced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway. Cellular signalling 17:1572-1577 (Pubitemid 41253996)
19. Chen CS, Wu CH, Lai YC, Lee WS, Chen HM, Chen RJ, Chen LC, Ho YS, Wang YJ (2008) NF-kappaB-activated tissue transglutaminase is involved in ethanol-induced hepatic injury and the possible role of propolis in preventing fibrogenesis. Toxicology 246:148-157
20. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518-527 (Pubitemid 351655218)
21. Wilkinson DS, Ogden SK, Stratton SA, Piechan JL, Nguyen TT, Smulian GA, Barton MC (2005) A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alphafetoprotein gene. Molecular and cellular biology 25:1200-1212
22. Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, Grossi F, Paganuzzi M (2008) Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Res 28:507-513 (Pubitemid 351362861)
23. He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, Matsui K, Shiono H, Okumura M, Nishida T, Tachibana I, Norioka N, Norioka S, Kawase I (2007) Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 98:1234-1240
24. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC, Chen CY, Chen KC, Yang TY, Chou TY, Wang WH, Whang-Peng J, Shih NY (2006) Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 12:5746-5754
25. Panasci L, Jean-Claude BJ, Vasilescu D, Mustafa A, Damian S, Damian Z, Georges E, Liu Z, Batist G, Leyland-Jones B (1996) Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem Pharmacol 52:1097-1102 (Pubitemid 26338268)
26. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC (1997) Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272:1682-1687 (Pubitemid 27043253)
27. Fujita T, Washio K, Takabatake D, Takahashi H, Yoshitomi S, Tsukuda K, Ishibe Y, Ogasawara Y, Doihara H, Shimizu N (2005) Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 117:670-682 (Pubitemid 41504558)
28. Ho YS, Duh JS, Jeng JH, Wang YJ, Liang YC, Lin CH, Tseng CJ, Yu CF, Chen RJ, Lin JK (2001) Griseofulvin potentiates antitumorigenesis effects of nocodazole through induction of apoptosis and G2/M cell cycle arrest in human colorectal cancer cells. Int J Cancer 91:393-401
29. Hermeking H, Eick D (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265:2091-2093
30. Ray RB, Steele R, Seftor E, Hendrix M (1995) Human breast carcinoma cells transfected with the gene encoding a c-myc promoter-binding protein (MBP-1) inhibits tumors in nude mice. Cancer Res 55:3747-3751
31. Kang Y, Cortina R, Perry RR (1996) Role of c-myc in tamoxifeninduced apoptosis estrogen-independent breast cancer cells. J Natl Cancer Inst 88:279-284 (Pubitemid 26073372)
32. Mandlekar S, Kong AN (2001) Mechanisms of tamoxifeninduced apoptosis. Apoptosis 6:469-477
33. Planas-Silva MD, Hamilton KN (2007) Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother Pharmacol 60:535-543
34. Zheng A, Kallio A, Harkonen P (2007) Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology 148:2764-2777 (Pubitemid 46984781)
35. Webb P, Lopez GN, Uht RM, Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443-456
36. Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, Nicolas JC, Lidereau R, Cohen PA (2005) Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat Cancer 12:75-92 (Pubitemid 40477089)
37. Quaedackers ME, van den Brink CE, van der Saag PT, Tertoolen LG (2007) Direct interaction between estrogen receptor alpha and NF-kappaB in the nucleus of living cells. Mol Cell Endocrinol 273:42-50
38. Kalaitzidis D, Gilmore TD (2005) Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab 16:46-52 (Pubitemid 40270849)
39. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, Benz CC (2005) Activation of nuclear factorkappaB (NFkappaB) identifies a high-risk subset of hormonedependent breast cancers. Int J Biochem Cell Biol 37:1130-1144 (Pubitemid 40311751)
40. Harvell DM, Richer JK, Singh M, Spoelstra N, Einlayson C, Borges VF, Elias AD, Horwitz KB (2008) Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat 112:489-501
41. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112 (Pubitemid 37328797)
42. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712 (Pubitemid 19147683)
43. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a southwest oncology group study. Clin Cancer Res 4:7-12 (Pubitemid 28062871)
44. John S, Nayvelt I, Hsu HC, Yang P, Liu W, Das GM, Thomas T, Thomas TJ (2008) Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res 68:7855-7863
45. Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP, Liang HJ (2008) Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy 54:357-363
46. Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B (2008) Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs 17:1533-1545
47. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-233 (Pubitemid 351380249)
48. Malorni L, Cacace G, Cuccurullo M, Pocsfalvi G, Chambery A, Farina A, Di Maro A, Parente A, Malorni A (2006) Proteomic analysis of MCF-7 breast cancer cell line exposed to mitogenic concentration of 17beta-estradiol. Proteomics 6:5973-5982 (Pubitemid 44851383)
49. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES (2005) Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neupositive breast cancer. Mol Cell Proteomics 4:1686-1696 (Pubitemid 41749262)
50. Ejma M, Misiuk-Hojlo M, Gorczyca WA, Podemski R, Szymaniec S, Kuropatwa M, Rogozinska-Szczepka J, Bartnik W (2008) Antibodies to 46-kDa retinal antigen in a patient with breast carcinoma and cancer-associated retinopathy. Breast Cancer Res Treat 110:269-271 (Pubitemid 351793877)